Background: Kinase fusions are rare and poorly characterized in breast cancer (BC). We aimed to characterize kinase fusions within a large cohort of advanced BC... Results: Twenty-seven of 4854 (0.6%) patients harbored fusions: 11 FGFR (five FGFR2, three FGFR3, three FGFR1), five BRAF, four NTRK1, two RET, two ROS1, one ALK, one ERBB2, and one MET... Conclusion: Kinase fusions in BC are extremely rare, and appear to be enriched in hormone-resistant, metastatic carcinomas and mutually exclusive with ESR1 mutations. The present study expands the spectrum of genetic alterations activating mitogen-activated protein kinase (MAPK) signaling that can substitute for ESR1 mutations in this setting. Molecular testing at progression after endocrine therapy should include fusion testing, particularly in the absence of ESR1 hotspot alterations, in an effort to identify additional therapeutic options which may provide substantial clinical benefit. READ ARTICLE
Annals of Oncology DOI:10.1016/j.annonc.2020.04.008
Authors: D. S. Ross, B. Liu, A. M. Schram, P. Razavi, S. M. Lagana, Y. Zhang, M. Scaltriti, J. F. Bromberg, M. Ladanyi, D. M. Hyman, A. Drilon, A. Zehir, R. Benayed, S. Chandarlapaty, J. F. Hechtman
